Checks heart artery plaque by CT scan in people with familial high cholesterol
Uses coronary CT scans to measure artery calcium in adults with familial hypercholesterolemia.
Plain-language title generated from the registry record
Registry title: Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)
Key facts
- Where
- Dijon, Lille, Lyon, Marseille, Nantes, Paris, Rennes, and Strasbourg, FranceSee the 9 sites
Where in France
- Chu Dijon BourgogneDijon, FranceTaking people
- CHRU LilleLille, FranceNot yet recruiting
- Hospices Civils de LyonLyon, FranceTaking people
- Hôpital de la Conception, AP-HMMarseille, FranceNot yet recruiting
- CHU NantesNantes, FranceTaking people
- Hôpital de la Pitié Salpêtrière - AP-HPParis, FranceTaking people
- Hôpital Saint Antoine AP-HPParis, FranceTaking people
- CHU RennesRennes, FranceTaking people
- CHU StrasbourgStrasbourg, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nantes University Hospital
- Trial code
- NCT06960902
- Record updated
- 19 March 2026
- Original description
The goal of this study (interventional clinical research not involving a health product) is to assess the prevalence of subclinical coronary atherosclerosis diagnosed by coronary CT angiography in heart failure patients in primary prevention, across different levels of cardiovascular risk defined by coronary artery calcium (CAC) score percentiles (based on data from the MESA study): low risk (≤25th percentile for age, sex, and ethnicity), intermediate risk (25th < CAC ≤ 75th percentile), and high risk (>75th percentile). The Patients will attend an on-site visit at inclusion (and must undergo a coronary CT angiography within 6 months following this visit), will be contacted by phone at 1 year and 2 years, and will return for an on-site visit at 30 months.Read full original descriptionShow less
Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia
The goal of this study (interventional clinical research not involving a health product) is to assess the prevalence of subclinical coronary atherosclerosis diagnosed by coronary CT angiography in heart failure patients in primary prevention, across different levels of cardiovascular risk defined by coronary artery calcium (CAC) score percentiles (based on data from the MESA study): low risk (≤25th percentile for age, sex, and ethnicity), intermediate risk (25th < CAC ≤ 75th percentile), and high risk (>75th percentile). The Patients will attend an on-site visit at inclusion (and must undergo a coronary CT angiography within 6 months following this visit), will be contacted by phone at 1 year and 2 years, and will return for an on-site visit at 30 months.
Inclusion: Person willing to sign the study consent form; Person affiliated with a current social security scheme; Person with a definite diagnosis of Familial Hypercholesterolemia, defined by a Dutch Lipid Clinic Network (DLCN) clinical-biological score > 8 and/or an identified causal mutation in the LDL receptor (LDLR) gene, apolipoprotein B100 gene, PCSK9 gene, or apolipoprotein E gene; Male aged 40 years or older, or female aged 50 years or older; Ability to understand French for questionnaire completion; Person not taking any lipid-lowering medication or on a stable dose of lipid-lowering therapy for at least one month prior to inclusion (three months for PCSK9 inhibitors) at Visit 1; Person not taking any antihypertensive medication or on a stable dose of antihypertensive therapy for at least one month at Visit 1; Person not taking any antidiabetic medication or on a stable dose of antidiabetic therapy for at least 3 months at Visit 1.
Exclusion: Subject who has received oral or intravenous corticosteroid therapy within the last 6 months; Subject receiving immunosuppressive or anticancer therapy; Patient with a history of atherosclerotic cardiovascular event (myocardial infarction, ischemic heart disease, coronary revascularization, ischemic stroke, carotid endarterectomy, lower limb arterial revascularization); Patient allergic to iodinated contrast agents; Subject with active cancer or in remission for less than 3 years; Severe renal insufficiency: estimated glomerular filtration rate (eGFR) according to the CKD-EPI formula ≤ 30 ml/min; Subject with a technical contraindication for coronary CT scan: patient diameter > 70 cm and/or weight > 250 kg; Subject with untreated or poorly controlled hypothyroidism; Subject refusing to participate; Subject under guardianship, curatorship, or judicial protection, or without social insurance coverage; Pregnant woman.